Abstract:Objective: To evaluate the safety of secukinumab (SEC) in the treatment of patients with axial spondyloarthritis (axSpA) and concurrent hepatitis B virus (HBV) infection or latent tuberculosis infection (LTBI). Methods: This is a retrospective cohort study. Adult axSpA patients with HBV infection or LTBI receiving SEC treatment for at least 3 months from March 2020 to July 2022 in Guangdong Provincial People's Hospital were included. Patients were screened for HBV infection and LTBI before SEC treatment. During follow-up, reactivation of HBV infection and LTBI was monitored. Relevant data were collected and analyzed. Results: A total of 43 axSpA patients with HBV infection or LTBI were included, of whom 37 were with HBV infection, 6 were with LTBI. Six out of thirty-seven (16.2%) patients with axSpA and concurrent HBV infection exhibited HBV reactivation after 9.0 ± 5.7 months of SEC treatment. Among them, 3 patients had chronic HBV infection and received anti-HBV prophylaxis, 2 patients had chronic HBV infection but did not receive anti-HBV prophylaxis, and 1 patient had occult HBV infection and did not receive antiviral prophylaxis. None of the 6 axSpA patients with LTBI developed reactivation of LTBI, whether received anti-TB prophylaxis or not. Conclusions: HBV reactivation can occur in axSpA patients with different types of HBV infection undergoing SEC treatment, whether receive antiviral prophylaxis or not. Close monitoring of HBV reactivation in axSpA patients with HBV infection undergoing SEC treatment is mandatory. Anti-HBV prophylaxis may be beneficial. In contrast, SEC may be safe in axSpA patients with LTBI, even in patients not receiving anti-TB prophylaxis. Key Points •Currently, most evidence about the safety of SEC in patients with HBV infection and LTBI were from patients with psoriasis. Our study adds data about the safety of SEC in Chinese axSpA patients with concurrent HBV infection or LTBI in real-world clinical setting. •Our study showed that HBV reactivation can occur in axSpA patients with different types of HBV infection undergoing SEC treatment, whether receive antiviral prophylaxis or not. •Close monitoring of serum HBV markers, HBV DNA load, and liver function is mandatory in axSpA patients with chronic, occult, and resolved HBV infection undergoing SEC treatment. Anti-HBV prophylaxis may be beneficial in all HBsAg-positive patients and HBsAg-negative, HBcAb-positive patients at high risk of HBV reactivation who are receiving SEC therapy. •None of the axSpA patients with LTBI, whether received anti-TB prophylaxis or not, developed reactivation of LTBI in our study. SEC may be safe in axSpA patients with LTBI, even in patients not receiving anti-TB prophylaxis.

Using secukinumab in a patient with endplate inflammation complicated by hepatitis B virus infection

Anti-TNF therapy in patients with HBV infection—analysis of 87 patients with inflammatory arthritis

Clinical Effectiveness of Ultrasound Guided Subacromial-Subdeltoid Bursa Injection of Botulinum Toxin Type A in Hemiplegic Shoulder Pain A Retrospective Cohort Study

Safety of secukinumab in the treatment of patients with axial spondyloarthritis and concurrent hepatitis B virus infection or latent tuberculosis infection

The Expression and Clinical Relevation of Osteopontin and IL-17 in Severe Hepatitis B

Consensus of Chinese Orthopaedic Experts on Diagnosis and Treatment of Ankylosing Spondylitis.

Predictors of Inflammatory Activity in Treatment-Naive Hepatitis B E-Antigen-negative Patients with Chronic Hepatitis B Infection

Risk of Tuberculosis and Hepatitis B Reactivation in Patients with Crohn's Disease on Ustekinumab: A Nationwide Real-World Study.

Mechanistic study on the improvement of immune inflammation in ankylosing spondylitis through regulation of the PI3K/AKT signaling pathway by Huangqin Qingre Chubi capsules

The role of secukinumab in the treatment of ankylosing spondylitis

Lubricin Expression in the Lumbar Endplate and Its Association with Modic Changes

Chinese Association for the Study of Pain: Experts Consensus on Ultrasound-Guided Injections for the Treatment of Spinal Pain in China (2020 Edition)

Potential Role of Peripheral Blood Lymphocyte Subsets in Rheumatoid Arthritis Patients Concurrent with Hepatitis B Virus Infection：A Retrospective Cohort Study

Screening for Hepatitis B Virus and Tuberculosis Infection in Patients with Moderate‐to‐severe Psoriasis Recruiting for Biological Therapy in China

Correspondence on ‘Effectiveness of secukinumab versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed to TNF inhibitors in the Swiss Clinical Quality Management cohort’ by Micheroli et al

The low back pain in patients with hip osteoarthritis: current knowledge on the diagnosis, mechanism and treatment outcome

The outcome study of rheumatic disease patients with chronic hepatitis B infection

Possibility of PD-1/PD-L1 Inhibitors for the Treatment of Patients with Chronic Hepatitis B Infection

Involvement of Th17 and Th1 Effector Responses in Patients with Hepatitis B

Protocol for lower back pain management: Insights from the French healthcare system

Association of hepatitis B infection with high-risk complications in total joint arthroplasty